Please assess the completion status of the following clinical trial:

Trial Title: Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients greater than or equal to 18 years old~* Confirmed diagnosis of Cushing's disease or acromegaly~Exclusion Criteria:~* Patients who require surgical intervention~* Patients receiving DPP-4 inhibitors or GLP-1 receptor agonists within 4 weeks prior to study entry~* HbA1c \> 10 % at screening~* Known hypersensitivity to somatostatin analogues Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Incretin based therapy (randomized group) (Type: EXPERIMENTAL): Participants randomized to the incretin based arm started with sitagliptin once daily. If sitagliptin did not control the participant's hyperglycemia, sitagliptin was stopped and participants switched to liraglutide once daily. If despite treatment with liraglutide, hyperglycemia was not controlled then the participant was eligible for rescue therapy with addition of insulin.
- Insulin (randomized group) (Type: EXPERIMENTAL): Participants randomized to the insulin arm started with once daily dose of basal insulin. The dose was up or down titrated at the discretion of the investigator. If blood glucose levels remained uncontrolled on basal insulin, participant switched to basal insulin plus prandial insulin.
- Non-Randomized Arm (Type: OTHER): This arm represents the non-randomized participants: Cushing's Disease (CD) or Acromegaly participants, who received pasireotide s.c. or LAR (long-acting release) respectively, but who were not randomized to the Incretin or Insulin arms.~For the purpose of analysis, this non-randomized arm is further split into 3 groups:~* Baseline insulin group (BL insulin) includes participants who were receiving insulin at study entry~* Oral antidiabetic drugs (OAD) group includes participants who developed hyperglycemia that was controlled by metformin and/or other background anti-diabetic treatment~* No OAD group includes participants who did not receive any anti-diabetic medication during the core phase of the trial

Based on this trial design, predict the completion outcome and termination type (if applicable).